NASDAQ:RLAY Relay Therapeutics Q3 2026 Earnings Report $16.99 -0.96 (-5.33%) As of 12:31 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Relay Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.40Beat/MissN/AOne Year Ago EPSN/ARelay Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.62 millionBeat/MissN/AYoY Revenue GrowthN/ARelay Therapeutics Announcement DetailsQuarterQ3 2026Date11/5/2026TimeAfter Market ClosesConference Call DateThursday, November 5, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Relay Therapeutics Earnings HeadlinesKrystal Biotech (NASDAQ:KRYS) and Relay Therapeutics (NASDAQ:RLAY) Head-To-Head SurveyOctober 8 at 6:15 AM | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Stock Has Consensus Price Target of $25.92 According to BrokeragesSeptember 28, 2026 | americanbankingnews.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.October 8 at 1:00 AM | Paradigm Press (Ad)Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comRelay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks TranscriptSeptember 10, 2026 | seekingalpha.comRelay Therapeutics CFO Sells 17,717 Shares for $350,000September 2, 2026 | fool.comSee More Relay Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Relay Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relay Therapeutics and other key companies, straight to your email. Email Address About Relay TherapeuticsRelay Therapeutics (NASDAQ:RLAY) is a clinical-stage biotechnology company focused on discovering and developing medicines for diseases driven by genetically defined targets, particularly in oncology. The company uses its proprietary Dynamo platform, which combines structural biology, computational modeling, machine learning and medicinal chemistry to study how proteins move and to identify potential drug-binding sites that may be difficult to address with conventional approaches. Relay’s pipeline has included targeted cancer therapies such as RLY-2608, an investigational oral inhibitor designed to selectively target PI3K-alpha mutations, and RLY-4008 (lirafugratinib), an investigational FGFR2 inhibitor developed for cancers with specific FGFR2 alterations. The company evaluates its candidates through clinical studies and may pursue commercialization and development collaborations as programs advance. Founded in 2016 and headquartered in Cambridge, Massachusetts, Relay Therapeutics conducts research and clinical development activities intended to support the global treatment of cancer and other serious diseases. Sanjiv Patel serves as the company’s president and chief executive officer.View Relay Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand ExplodesDoes Lemonade’s Growth Signal Profits Ahead?Wall Street Is Betting These 3 Beaten-Down Stocks Have More Room to Run Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
